8-K: Achieve Life Sciences Announces $50 Million At-the-Market Offering

Achieve Life Sciences has entered into an agreement with Jefferies LLC to sell up to $50 million of its common stock through an at-the-market offering program.

Summary

• Achieve Life Sciences has established an at-the-market (ATM) offering program to sell up to $50 million of its common stock.
• The company will use Jefferies LLC as a sales agent for the program.
• Shares will be sold at the company's discretion, from time to time.
• Jefferies will receive a commission of up to 3.0% of the gross proceeds from the sales.
• The company intends to use the net proceeds to fund clinical development of cytisinicline, related research, and for general corporate purposes.
• The ATM program will terminate upon the sale of the maximum amount or termination of the agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The ATM offering is a standard financial move for a company in this stage, providing necessary funding but also introducing potential dilution. The focus on cytisinicline development is a positive sign for the company's future.

Positives

• The ATM offering provides Achieve Life Sciences with a flexible way to raise capital.
• The funds raised will support the clinical development of cytisinicline, a key focus for the company.
• The agreement allows the company to control the timing and amount of shares sold.

Negatives

• The offering could dilute existing shareholders' ownership.
• The company will incur fees and expenses related to the offering, including a 3% commission to Jefferies.
• There is no guarantee that the company will sell the full $50 million of shares.

Risks

• The company's stock price could be negatively impacted by the increased supply of shares.
• The success of the cytisinicline development program is not guaranteed.
• The company may need to raise additional capital in the future if the ATM offering is not sufficient.

Future Outlook

The company intends to use the net proceeds from the ATM program to fund clinical development of cytisinicline, related research, and for working capital and general corporate purposes.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, especially those in the clinical development stage, as it allows them to access funds without the need for a large, dilutive secondary offering.

Comparison to Industry Standards

• Many biotech companies, such as Xencor and BioMarin, have utilized ATM offerings to fund their research and development activities.
• The 3% commission to Jefferies is within the typical range for ATM offerings in the biotech sector.
• The size of the offering, $50 million, is relatively common for companies of Achieve Life Sciences' size and stage of development.
• Compared to a traditional secondary offering, an ATM offering provides more flexibility and less immediate dilution.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• Employees may benefit from the company's increased financial stability.
• Customers may benefit from the continued development of cytisinicline.
• Creditors may view the company as a lower credit risk due to the increased capital.

Next Steps

• Achieve Life Sciences will begin selling shares through the ATM program at its discretion.
• The company will use the proceeds to fund its clinical development and research activities.
• The company will continue to monitor market conditions and adjust its sales strategy as needed.

Key Dates

Keywords

at-the-market offering, ATM program, capital raise, common stock, cytisinicline, Jefferies LLC, clinical development, equity financing